Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 4, 2013, Pages 351-359

  Coiffier, Bertrand ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

mTOR; Non Hodgkin lymphoma

Indexed keywords

ALEMTUZUMAB; AMIODARONE; ANTIBIOTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CHLORAMBUCIL; CLADRIBINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LENALIDOMIDE; METHOTREXATE; MITOXANTRONE; PENTAMIDINE; PREDNISOLONE; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL PRACTICE; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; EPISTAXIS; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAINTENANCE THERAPY; MANTLE CELL LYMPHOMA; MONOTHERAPY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRESCRIPTION; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT CANCER; REVIEW; THROMBOCYTOPENIA;

MTOR; NON-HODGKIN LYMPHOMA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; LYMPHOMA, MANTLE-CELL; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SIROLIMUS;

EID: 84880760560     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.04.003     Document Type: Review

References (62)

1. S. Cortelazzo, M. Ponzoni, and A.J. Ferreri Mantle cell lymphoma Crit Rev Oncol Hematol 82 2012 78 101
2. M. Dreyling, H.C. Kluin-Nelemans, and S. Bea Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network Leuk Lymphoma 54 2013 699 707
3. S. Dietrich, B. Tielesch, and M. Rieger Patterns and outcome of relapse after autologous stem cell transplantation for mantle cell lymphoma Cancer 117 2011 1901 1910
4. A. Herrmann, E. Hoster, and T. Zwingers Improvement of overall survival in advanced stage mantle cell lymphoma J Clin Oncol 27 2009 511 518
5. T.E. Witzig Current treatment approaches for mantle-cell lymphoma J Clin Oncol 23 2005 6409 6414 (Pubitemid 46222241)
6. M. Dreyling, G. Lenz, and E. Hoster Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network Blood 105 2005 2677 2684 (Pubitemid 40450320)
7. R. Delarue, C. Haioun, and V. Ribrag CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte Blood 121 2013 48 53
8. O. Hermine, E. Hoster, and J. Walewski Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net) Blood 116 2010 (ASH Annual Meeting Abstracts) (abstract 110)
9. S. Harel, R. Delarue, and V. Ribrag Treatment of younger patients with mantle cell lymphoma Semin Hematol 48 2011 194 207
10. H.C. Kluin-Nelemans, E. Hoster, and O. Hermine Treatment of older patients with mantle-cell lymphoma N Engl J Med 367 2012 520 531
11. G. Hess Temsirolimus for the treatment of mantle cell lymphoma Expert Rev Hematol 2 2009 631 640
12. G. Hess, R. Herbrecht, and J. Romaguera Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma J Clin Oncol 27 2009 3822 3829
13. R.I. Fisher, S.H. Bernstein, and B.S. Kahl Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma J Clin Oncol 24 2006 4867 4874 (Pubitemid 46655613)
14. J. Ruan, P. Martin, and R.R. Furman Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma J Clin Oncol 29 2011 690 697
15. T.M. Habermann, I.S. Lossos, and G. Justice Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma Br J Haematol 145 2009 344 349
16. P.H. Wiernik, I.S. Lossos, and J.M. Tuscano Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma J Clin Oncol 26 2008 4952 4957
17. M. Wang, L. Fayad, and N. Wagner-Bartak Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial Lancet Oncol 13 2012 716 723
18. P. Argyriou, P. Economopoulou, and S. Papageorgiou The role of mTOR inhibitors for the treatment of B-cell lymphomas Adv Hematol 2012 2012 435342
19. B. Coiffier, and V. Ribrag Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies Leuk Lymphoma 50 2009 1916 1930
20. A. Younes, and N. Samad Utility of mTOR inhibition in hematologic malignancies Oncologist 16 2011 730 741
21. R.T. Abraham, and J.J. Gibbons The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy Clin Cancer Res 13 2007 3109 3114 (Pubitemid 46944891)
22. B. Shor, W.G. Zhang, and L. Toral-Barza A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis Cancer Res 68 2008 2934 2943 (Pubitemid 351556294)
23. D. Del Bufalo, L. Ciuffreda, and D. Trisciuoglio Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus Cancer Res 66 2006 5549 5554 (Pubitemid 43927103)
24. P. Perez-Galan, M. Dreyling, and A. Wiestner Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era Blood 117 2011 26 38
25. J. Dal Col, P. Zancai, and L. Terrin Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma Blood 111 2008 5142 5151
26. E. Peponi, E. Drakos, and G. Reyes Activation of mammalian target of rapamycin signaling promotes cell cycle progression and protects cells from apoptosis in mantle cell lymphoma Am J Pathol 169 2006 2171 2180 (Pubitemid 351181976)
27. L. Wang, W.Y. Shi, and Z.Y. Wu Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma J Hematol Oncol 3 2010 30
28. V.Y. Yazbeck, D. Buglio, and G.V. Georgakis Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma Exp Hematol 36 2008 443 450 (Pubitemid 351384743)
29. S.M. Ansell, D.J. Inwards, and K.M. Rowland Jr. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group Cancer 113 2008 508 514
30. T.E. Witzig, S.M. Geyer, and I. Ghobrial Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma J Clin Oncol 23 2005 5347 5356 (Pubitemid 46206988)
31. D. Decaudin, J. Bosq, and G. Tertian Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas J Clin Oncol 16 1998 579 583 (Pubitemid 28135602)
32. C. Dumontet, F. Morschhauser, and P. Solal-Celigny Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma Br J Haematol 113 2001 772 778 (Pubitemid 32524402)
33. K. Tobinai, T. Watanabe, and M. Ogura Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin's lymphoma J Clin Oncol 24 2006 174 180 (Pubitemid 46630510)
34. S.M. Ansell, H. Tang, and P.J. Kurtin Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study Lancet Oncol 12 2011 361 368
35. Hess G, Keller U, Atta J, et al. Temsirolimus in combination with bendamustine and rituximab for the treatment of relapsed mantle cell and follicular lymphoma: report on an ongoing phase I/II trial. Presented at: Annual Meeting of the American Society of Hematology; December 10-13, 2011; San Diego, CA. Abstract 2697.
36. Torisel [annex 1 summary of product characteristics]. European Medicines Agency. Available at: www.emea.europa.eu/docs/en-GB/document-library/EPAR--- Product-Information/human/000799/WC500039912.pdf. Accessed October 18, 2011.
37. Hess G, Kang L, Moran PJ. Temsirolimus in patients with relapsed/refractory mantle cell lymphoma: does prognostic risk affect outcomes? Presented at: 17th Congress of the European Hematology Association; Amsterdam, The Netherlands; June 14-17, 2012. Abstract 0250.
38. C.H. Geisler, A. Kolstad, and A. Laurell The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT) Blood 115 2010 1530 1533
39. E. Hoster, M. Dreyling, and W. Klapper A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Blood 111 2008 558 565
40. A. Bair, G. Hess, and J. Boni Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma J Clin Oncol 29 2011 abstract TPS222
41. P. Cai, R. Tsao, and M.E. Ruppen In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites Drug Metab Dispos 35 2007 1554 1563 (Pubitemid 47296048)
42. J. Boni, C. Leister, and J. Burns Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications J Clin Pharmacol 47 2007 1430 1439 (Pubitemid 47624594)
43. J.P. Boni, C. Leister, and J. Burns Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus Br J Cancer 98 2008 1797 1802 (Pubitemid 351748841)
44. J.P. Boni, B. Hug, and C. Leister Intravenous temsirolimus in cancer patients: clinical pharmacology and dosing considerations Semin Oncol 36 2009 S18 S25
45. J. Boni, R. Abbas, and C. Leister Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus Cancer Chemother Pharmacol 64 2009 263 270
46. E.J. Filippone, J.M. Carson, and R.A. Beckford Sirolimus-induced pneumonitis complicated by pentamidine-induced phospholipidosis in a renal transplant recipient: a case report Transplant Proc 43 2011 2792 2797
47. G. Hudes, M. Carducci, and P. Tomczak Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281 (Pubitemid 46849157)
48. J.P. Maroto, G. Hudes, and J.P. Dutcher Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus J Clin Oncol 29 2011 1750 1756
49. C. Deng, S. Lee, and O.A. O'Connor New strategies in the treatment of mantle cell lymphoma Clin Cancer Res 18 2012 3499 3508
50. M.S. Noel, J.W. Friedberg, and P.M. Barr Novel agents in mantle cell lymphoma Best Pract Res Clin Haematol 25 2012 191 200
51. S. Parekh, M.A. Weniger, and A. Wiestner New molecular targets in mantle cell lymphoma Semin Cancer Biol 21 2011 335 346
52. S.M. Smith Targeting mTOR in mantle cell lymphoma: current and future directions Best Pract Res Clin Haematol 25 2012 175 183
53. K.W. Yee, Z. Zeng, and M. Konopleva Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies Clin Cancer Res 12 2006 5165 5173 (Pubitemid 44453345)
54. C. Renner, P.L. Zinzani, and R. Gressin A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma Haematologica 97 2012 1085 1091
55. J.W. Friedberg, J. Sharman, and J. Sweetenham Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 2010 2578 2585
56. B.J. Lannutti, S.A. Meadows, and S.E. Herman CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability Blood 117 2011 591 594
57. Papadopoulis KP, Abrisqueta P, Chambers G, et al. A phase I dose expansion cohort study of the safety, pharmacokinetics and pharmacodynamics of SAR245409 (S09), an orally administered PI3K/mTOR inhibitor, in patients with lymphoma. Presented at: 53rd American Society of Hematology Annual Meeting; December 10-13, 2011. San Diego, CA. Abstract 1608.
58. R.H. Advani, J.J. Buggy, and J.P. Sharman Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J Clin Oncol 31 2013 88 94
59. Wang L, Martin P, Blum KA, et al. The Bruton's tyrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. Presented at: 53rd American Society of Hematology Annual Meeting; December 10-13, 2011; San Diego, CA. Abstract 442.
60. A. Kim, S. Park, and J.E. Lee The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells Leuk Res 36 2012 912 920
61. L. Rosich, S. Xargay-Torrent, and M. Lopez-Guerra Counteracting autophagy overcomes resistance to everolimus in mantle cell lymphoma Clin Cancer Res 18 2012 5278 5289
62. S. Kirschey, S. Wagner, and G. Hess Relapsed and/or refractory mantle cell lymphoma: what role for temsirolimus? Clin Med Insights Oncol 6 2012 153 164